BioCardia Reports Q3 Financial Results
BioCardia, a Sunnyvale-based developer of cellular therapeutics, reported its third-quarter financial results. The company highlighted progress in its clinical trials for cardiovascular therapies, including the CardiAMP Heart Failure Trial. BioCardia plans to release top-line data in the first quarter of 2025 and has received FDA approval for protocol amendments to increase patient eligibility. The company also reported a reduction in net loss compared to the previous year, reflecting its ongoing efforts to manage expenses and advance its therapeutic programs.